Business Description
Sorrento Therapeutics Inc
NAICS : 325414
SIC : 8731
ISIN : US83587F2020
Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -56.39 | |||||
| 12-1 Month Momentum % | -57.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -378.56 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-Forward-EBIT | -2.7 | |||||
| EV-to-Forward-Revenue | 2.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sorrento Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 61.341 | ||
| EPS (TTM) (€) | -0.202 | ||
| Beta | 0 | ||
| Volatility % | 76.35 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.12295 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -57.25 | ||
| 52-Week Range (€) | 0.1337 - 2.79 | ||
| Shares Outstanding (Mil) | 547.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sorrento Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sorrento Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sorrento Therapeutics Inc Frequently Asked Questions
What is Sorrento Therapeutics Inc(FRA:8STN)'s stock price today?
The current price of FRA:8STN is €0.30. The 52 week high of FRA:8STN is €2.79 and 52 week low is €0.13.
When is next earnings date of Sorrento Therapeutics Inc(FRA:8STN)?
The next earnings date of Sorrento Therapeutics Inc(FRA:8STN) is 2024-11-29 Est..
Does Sorrento Therapeutics Inc(FRA:8STN) pay dividends? If so, how much?
Sorrento Therapeutics Inc(FRA:8STN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers